These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32323879)

  • 21. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
    Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
    J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.
    Mao R; Li K; Cai JQ; Luo S; Turner M; Blazer D; Zhao H
    Ann Surg; 2021 Aug; 274(2):e126-e133. PubMed ID: 31478977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
    Lu ZH; Li J; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li Y; Shen L
    Med Oncol; 2013; 30(3):664. PubMed ID: 23864251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis.
    Zhang WY; Zhang WJ; Bai Y; Yuan HH; Liu F; Gao J; Gong YF; Jiang B
    Asian Pac J Cancer Prev; 2013; 14(1):381-6. PubMed ID: 23534757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
    Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
    Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases.
    Kanetkar AV; Patkar S; Khobragade KH; Ostwal V; Ramaswamy A; Goel M
    J Gastrointest Cancer; 2019 Jun; 50(2):298-303. PubMed ID: 29435905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
    Pei X; Xiang L; Ye S; He T; Cheng Y; Yang W; Wu X; Yang H
    Gynecol Oncol; 2017 Dec; 147(3):589-596. PubMed ID: 28954697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma.
    Iyoda A; Hiroshima K; Moriya Y; Takiguchi Y; Sekine Y; Shibuya K; Iizasa T; Kimura H; Nakatani Y; Fujisawa T
    Ann Thorac Surg; 2006 Nov; 82(5):1802-7. PubMed ID: 17062251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
    Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
    Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
    Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
    Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
    Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
    J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.
    Petrioli R; Sabatino M; Roviello F; Marrelli D; Nastri G; Marsili S; Correale P; Pozzessere D; Messinese S; De Martino A; Tani F; Marzocca G; Lorenzi M; Civitelli S; Tanzini G; Pinto E; Francini G
    Hepatogastroenterology; 2005; 52(65):1626-30. PubMed ID: 16201130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
    Kim S; Paget-Bailly S; Messager M; Nguyen T; Mathieu P; Lamfichekh N; Fein F; Fratté S; Cléau D; Lakkis Z; Jary M; Sakek N; Jacquin M; Foubert A; Bonnetain F; Mariette C; Fiteni F; Borg C
    Eur J Surg Oncol; 2017 Jan; 43(1):218-225. PubMed ID: 27425578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
    Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
    J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
    Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
    Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
    Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
    Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.